官方公告：对一上市深企立案调查

Core Viewpoint - The China Securities Regulatory Commission (CSRC) has initiated an investigation into Shenzhen Yahui Long Biotechnology Co., Ltd. (Yahui Long) for allegedly misleading statements in their announcements regarding a strategic cooperation framework agreement [1][2]. Group 1: Investigation Details - On February 6, 2026, the CSRC issued a notice to Yahui Long, stating that the company is under investigation for suspected violations of information disclosure laws [2]. - The investigation is linked to a previous announcement made by Yahui Long on January 6, 2026, regarding a strategic cooperation agreement with Shenzhen Brain Machine Starlink Technology Co., Ltd. [2][3]. - The CSRC's decision to investigate is based on the provisions of the Securities Law of the People's Republic of China and the Administrative Penalty Law [2]. Group 2: Company Announcements and Responses - Yahui Long clarified that the strategic cooperation agreement is a non-binding intention and does not involve specific financial commitments, thus not requiring board or shareholder approval [2]. - The Shanghai Stock Exchange (SSE) sent an inquiry letter to Yahui Long on the same day, emphasizing the need for accurate and complete information disclosure, especially regarding the hot market concept of "brain-machine interfaces" [2][3]. Group 3: Regulatory Concerns - The SSE highlighted inconsistencies in Yahui Long's announcements regarding the technical aspects of the cooperation with Brain Machine Starlink, as well as insufficient risk disclosures related to collaboration feasibility and uncertainties [3]. - The SSE determined that Yahui Long's actions violated relevant regulations of the Shanghai Stock Exchange's listing rules and self-regulatory guidelines, leading to a regulatory warning for the company's then-secretary of the board, Wang Mingyang [3].